2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid

• ChemBase编号: 391
• 分子式: C15H11I4NO4
• 平均质量: 776.87002
• 单一同位素质量: 776.68669984
• SMILES: Ic1cc(CC(N)C(=O)O)cc(I)c1Oc1cc(I)c(O)c(I)c1
• Canonical SMILES: OC(=O)C(Cc1cc(I)c(c(c1)I)Oc1cc(I)c(c(c1)I)O)N
• InChI: InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)
• InChIKey: XUIIKFGFIJCVMT-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
• IUPAC传统名: thyroxine
• 商标名: Choloxin; Dynothel; Lisolipin; Eulipos
• 别名: 3,5,3′,5′-Tetraiodo-d-thyronine Sodium; Dekstrotyroksiininatrium; Dextrothyroxinum Natricum; Dextrotiroxina sódica; Dextrotyroxinnatrium; D-Thyroxine Sodium; Sodium 4-O-(4-hydroxy-3,5-di-iodophenyl)-3,5-di-iodo-d-tyrosinate hydrate; Dextrothyroxine; O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine; DL-THYROXINE, NA; 3,5,3',5'-tetraiodo-L-thyronine; Levothyroxine

登记号

• CAS号: 51-48-9; 51-49-0
• MDL号: MFCD00063058
• PubChem SID: 160963854
• PubChem CID: 853; 5819
• CHEBI ID: 18332
• ATC码: H03AA01
• CHEMBL: 1624
• Chemspider ID: 5614
• DrugBank ID: DB00451
• 医学主题词(MeSH): Thyroxine
• 美国药典/FDA物质标识码: Q51BO43MG4
• 维基百科标题: Levothyroxine

理论计算性质

JChem

• Acid pKa: 0.27336746
• 质子受体: 4
• 质子供体: 3
• LogD (pH = 5.5): 3.722463
• LogD (pH = 7.4): 3.4409168
• Log P: 3.727307
• 摩尔折射率: 126.788 cm^3
• 极化性: 50.46104 Å^3
• 极化表面积: 92.78 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 1.15
• LOG S: -4.94
• 溶解度: 8.98e-03 g/l

分子性质

理化性质

• 溶解度: slightly soluble (0,105 mg·l^-1 at 25 °C) in water
• 熔点: 231–233 °C
• 疏水性(logP): 4

安全信息

• 保存注意事项: IRRITANT
• 安全公开号: S22, S24/25
• TSCA收录: false

药理学性质

• 给药途径: Oral, intravenous
• 生物利用度: ~100%
• 排泄: Through feces and urine
• 半衰期: ca. 7 days (in hyperthyroidism 3-4 days, in hypothyroidism 9-10 days)
• 代谢: Mainly in liver, kidneys, brain and muscles
• 法定药品分级: Rx
• 妊娠期药物分类: A (US)

详细说明

MP Biomedicals - 05207619

MP Biomedicals Rare Chemical collection

DrugBank - DB00509

• Drug Groups: approved
• Description: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism. [PubChem]
• Indication: Used to lower high cholesterol levels in the blood.
• Pharmacology: Dextrothyroxine, the dextrorotary isomer of the synthetic thyroxine, is a antihyperlipidemic.
• Toxicity: Symptoms of dextrothyroxine overdose are unknown.
• Affected Organisms: Humans and other mammals
• External Links: Wikipedia